Comparing the current results to its competitors, Livanova Plc reported Revenue increase in the 1 quarter 2026 by 14.2 % year on year. The sales growth was above Livanova Plc's competitors' average revenue growth of 4.39 %, achieved in the same quarter.
Livanova Plc's Comment on Competition and Industry Peers
LivaNova operates in the global medical device market, with sales in over 100 countries. The market is characterized by technological advances and scientific discoveries. LivaNova's competitors include large manufacturers with multiple business lines as well as smaller manufacturers offering specialized products. The company also competes with providers of alternative medical therapies, pharmaceuticals, and surgical interventions. Market competition is influenced by physician advisories, regulatory safety alerts, and publications regarding products from LivaNova and its competitors, which can impact market share. Additional factors affecting competition include developments in managed care, economically motivated customers, healthcare provider consolidation, increased competition, and declining reimbursement rates. To maintain competitiveness, LivaNova must continue to innovate or acquire advanced technology.
November 24, 2025
LONDON LivaNova PLC (Nasdaq: LIVN), a leading force in medical technology, has marked significant milestones with advancements in its neuromodulation therapies. The U.S. Centers for Medicare and Medicaid Services (CMS) recently assigned LivaNova’s Vagus Nerve Stimulation (VNS) Therapy a new classification, which is expected to boost reimbursement levels for procedures treating drug-resistant epilepsy (DRE). Alongside this clinical and financial triumph, LivaNova has unveiled encouraging 12-month results from its OSPREY clinical study, underscoring the viability of its aura6000 System for treating moderate to severe obstructive sleep apnea (OSA). Elevated Reimbursement Status Getting the nod from CMS is no ...
Edwards Lifesciences Corporations business model focuses on the development and commercialization of advanced medical technologies that enhance the diagnosis and treatment of heart disease, emphasizing innovative heart valves and critical care monitoring solutions. The company serves a diverse customer base, including hospitals and direct-to-patient markets, with a strong commitment to improving patient outcomes and quality of life.
Haemonetics Corporation's business model revolves around providing innovative solutions and technologies for the collection, processing, and management of blood and its components.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Inspire Medical Systems Inc operates on a direct-to-patient business model, focused on developing and commercializing innovative medical devices for patients suffering from sleep apnea. The company's business model revolves around providing a unique therapy solution through the development of its proprietary Inspire therapy system, which includes a surgically implanted device that stimulates the upper airway during sleep. By targeting both physicians and patients, Inspire Medical Systems aims to improve clinical outcomes and bring relief to those with unmet needs in the field of sleep apnea treatment.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Sources:
Livanova Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Livanova Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
